NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Arcturus Therapeutics Holdings Inc. ARCT
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$82.0M
▼ 46.1% vs FY2024
EPS · FY25
$-2.40
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-28.9%
Net margin · FY25
-80.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 82.0M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 80 cents on every revenue dollar this year.
Per share
USD -2.40
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-28.9%
Return on equity, FY2025
ROE
Operating margin-93.0%
Net margin-80.2%
Return on assets-21.4%
Each USD of equity lost 29 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+53.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−26.4%
+53.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+8.5%
Change, 10 years—
The share count grew 8% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 271.1M
total assets, end of FY2025
Total assetsUSD 271.1M
EquityUSD 214.0M
CashUSD 230.9M
Current ratio6.64×
Equity funds 79% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.1
0.2
0.2
0.2
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
0.0
−0.2
−0.1
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
Income tax $B
·
−0.0
0.0
0.0
·
·
·
·
Net income $B
−0.1
−0.1
−0.0
0.0
−0.2
−0.1
−0.0
−0.0
EPS, diluted $
−2.40
−3.00
−1.12
0.35
−7.74
−3.55
−2.15
−2.16
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−28.9
−31.2
−10.8
3.8
−65.2
−34.2
−131.8
−159.7
Shares out B
0.03
0.03
0.03
0.03
0.03
0.03
0.02
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed